ArticleJournal of Cancer2019
Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- PMN-MDSCs-derived exosomal S100A9 drives breast cancer progression by enhancing cancer stemness and CXCL5-mediated metastatic potential.Cell death discovery · 2026Article
- Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer.medRxiv : the preprint server for health sciences · 2026Article
- S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Machine learning approach identifies inflammatory gene signature for predicting survival outcomes in hepatocellular carcinoma.Scientific reports · 2024Article
- Identifying epithelial-mesenchymal transition-related genes as prognostic biomarkers and therapeutic targets of hepatocellular carcinoma by integrated analysis of single-cell and bulk-RNA sequencing data.Translational cancer research · 2024Article
- Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression.International journal of molecular sciences · 2024Review
- Establishment and Evaluation of Exosomes-Related Gene Risk Model in Hepatocellular Carcinoma.Biochemical genetics · 2024Article
- EMT-related gene risk model establishment for prognosis and drug treatment efficiency prediction in hepatocellular carcinoma.Scientific reports · 2023Article
- Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Metastatic Colon Cancer Treatment Using S100A9-Targeted Cowpea Mosaic Virus Nanoparticles.Biomacromolecules · 2022Article
- Differential plasma proteomes of the patients withHeliyon · 2022Article
- S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma.International journal of molecular sciences · 2022Review
- Review
- Immune-related gene signature to predict TACE refractoriness in patients with hepatocellular carcinoma based on artificial neural network.Frontiers in genetics · 2022Article
- A novel immune-related gene signature predicts the prognosis of hepatocellular carcinoma.Frontiers in oncology · 2022Article
- High S100A9Aging · 2021Article
- Glycopatterns and Glycoproteins Changes in MCN and SCN: A Prospective Cohort Study.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.